KRAS and neoplasm: ,2 At the genetic level, around 80% of patients carry an oncogenic KRAS mutation at an early stage of tumor development, followed by loss of function mutations in the tumor suppressors TP53, SMAD4, and CDKN2A (between 90% and 50%) leading to PDAC.3